This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
Journal of Hematology & Oncology Open Access 04 May 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701–4707.
Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007; 110: 4614–4617.
Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M et al Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969–2976.
Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–1339.
Chen J, Schmitt A, Giannopoulos K, Chen B, Rojewski M, Döhner H et al. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int J Oncol 2007; 31: 1133–1139.
Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 2005; 105: 1135–1143.
Acknowledgements
The work was funded by the Program from Science and Technology Department of Zhejiang Povince (2008C23047).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Luo, Y., Lai, XY., Tan, YM. et al. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia 23, 1171–1174 (2009). https://doi.org/10.1038/leu.2008.401
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.401
This article is cited by
-
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
Journal of Hematology & Oncology (2020)
-
Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia
Annals of Hematology (2017)
-
Allogeneic transplantation for CML in the TKI era: striking the right balance
Nature Reviews Clinical Oncology (2016)
-
Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase
Drugs & Aging (2016)
-
Pushing the envelope—nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation
Bone Marrow Transplantation (2015)